[Document Name]Written Statement [Reference Number]PF13046 [Date of submission] Reiwa 3(2021) February 15 [Recipient] Patent Office chief administrative judge [Indication of case] [Appeal or trial number]Appeal 2020 - 6843 [Application number] Japanese Patent Application No. 2017-93750 [Person who submits written statement] [Identification Number]513084469 [Name] ModernaTX, Inc.

[Representative]

[Identification Number]100105957

[Patent attorney] [Name]ONDA, Makoto

[The contents of report] An opinion is stated to below about the Report of Reconsideration by Examiner before Appeal as of Reiwa 2(2020) September 1. [in the above-mentioned Report of Reconsideration by Examiner before Appeal] [the correction in Claim 1 of the description to the Written Amendment as of Reiwa 2(2020) May 20] It is not what carried out within the scope of matters disclosed in the Description, Claims, or Drawings originally attached to the application, regulation of Patent Law Article 17bis(3) is violated, and it is judged that it corresponds to a New Matter. The examiner is among the data in Table 57 in Description of this application as the Reason [result / of NPA-072-1 which was not extracted in Table B of the description to the Written Amendment (Formality) as of Reiwa 2(2020) July 2, NPA-074-1, and NPA-076-1] A proteinic expression level increases compared with the case where mean particle diameter is less than 85 nm when the mean particle diameter of a lipid nano particle is 85 nm or more, The tendency for a proteinic expression level to increase compared with the case where mean particle diameter exceeds 153 nm when the mean particle diameter of a lipid nano particle is 153 nm or less cannot be found out, about the mean particle diameter of a lipid nano particle, making 85 nm into a minimum and making 153 nm into a maximum is described -- ** -- the thing of the purport that it cannot be said that it is equal is described. However, the applicant is sure that the correction in Claim 1 of the description to the Written Amendment as of Reiwa 2(2020) May 20 is what Patent Law Article 17bis(3) comply with. This is because ********** [the correction concerned] in a relation with the matter described in the description etc. as filed of this application, and since

it is as having stated in the Written Amendment (Formality) as of Reiwa 2(2020) July 2 for details, it is not repeated here. However, when the correction concerned still has a doubt about a New Matter, it is ready to correct deleting the description by "The protein coded by the aforementioned polynucleotide is revealed on a higher level" added to Claim 1, for example by the correction concerned etc. Although the judgment about the Inventive Step of the present invention is not shown in the above-mentioned Report of Reconsideration by Examiner before Appeal, the applicant is sure that an applicant is not that in which the person skilled in the art was able to invent easily based on invention to which the present invention was described in the cited document. Since the Reason is also in the Written Amendment (Formality) as of Reiwa 2(2020) July 2 and is as having already stated, it is not repeated here. However, when the Inventive Step of the present invention still has a doubt, an applicant is ready to perform a mist beam and further correction. This application is the divisional application (child application) which makes original application

Japanese Patent Application No. 2015-504571 (parent application), as this is also

described in the Written Amendment (Formality) as of Reiwa 2(2020) July 2. Japanese Patent Application No. 2020-088048 (grandchild application) of the divisional application which makes this application original application is also going to exist, and an applicant is going to aim at right-ization of invention with the another present invention in Japanese Patent Application No. 2020-088048 which is grandchild application. In order to regard as what carried out grandchild application (Japanese Patent Application No. 2020-088048) at the time of parent application (Japanese Patent Application No. 2015-504571) and to carry out an examination, Since this application which is child application needs to satisfy all the requirements for division to parent application (Japanese Patent Application No. 2015-504571), there is a strong desire to avoid the situation which refusal decides with division of this application of patent application not complying with requirements. Such a situation is taken into consideration, and when it is presumed that it is that by which this application should still be refused, I would like to have an opportunity of correction kindly and please give me care.